{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T19:32:27Z","timestamp":1790105547609,"version":"4.0.1"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001661","name":"Universit\u00e4t Heidelberg","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"German Cancer Aid","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.canlet.2021.02.016","type":"journal-article","created":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T06:30:29Z","timestamp":1614407429000},"page":"1-10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["KIF11 inhibitors filanesib and ispinesib inhibit meningioma growth in vitro and in vivo"],"prefix":"10.1016","volume":"506","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7571-8947","authenticated-orcid":false,"given":"Gerhard","family":"Jungwirth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junguo","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5994-993X","authenticated-orcid":false,"given":"Montadar Alaa","family":"Eddine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9146-0808","authenticated-orcid":false,"given":"Mahmoud","family":"Moustafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2821-4361","authenticated-orcid":false,"given":"Rolf","family":"Warta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6411-4811","authenticated-orcid":false,"given":"Juergen","family":"Debus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Unterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Abdollahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christel","family":"Herold-Mende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2021.02.016_bib1","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/noz150","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016","volume":"21","author":"Ostrom","year":"2019","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.canlet.2021.02.016_bib2","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health organization classification of tumors of the central nervous system: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.canlet.2021.02.016_bib3","doi-asserted-by":"crossref","first-page":"101562","DOI":"10.1016\/j.canep.2019.07.001","article-title":"Incidence, mortality and outcome of meningiomas: a population-based study from Germany","volume":"62","author":"Holleczek","year":"2019","journal-title":"Cancer Epidemiology"},{"key":"10.1016\/j.canlet.2021.02.016_bib4","doi-asserted-by":"crossref","first-page":"i18","DOI":"10.1093\/neuonc\/noy136","article-title":"International consortium on meningiomas, advances in multidisciplinary therapy for meningiomas","volume":"21","author":"Brastianos","year":"2019","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.canlet.2021.02.016_bib5","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/neuonc\/not330","article-title":"Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review","volume":"16","author":"Kaley","year":"2014","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.canlet.2021.02.016_bib6","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1126\/science.1233009","article-title":"Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO","volume":"339","author":"Clark","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.canlet.2021.02.016_bib7","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s40478-019-0793-4","article-title":"Intraventricular meningiomas frequently harbor NF2 mutations but lack common genetic alterations in TRAF7, AKT1, SMO, KLF4, PIK3CA, and TERT","volume":"7","author":"Jungwirth","year":"2019","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.canlet.2021.02.016_bib8","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv377","article-title":"TERT promoter mutations and risk of recurrence in meningioma","volume":"108","author":"Sahm","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.canlet.2021.02.016_bib9","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/neuonc\/nox094","article-title":"Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas","volume":"19","author":"Shankar","year":"2017","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.canlet.2021.02.016_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jnci\/djw320","article-title":"Durable control of metastatic AKT1-mutant WHO grade 1 meningothelial meningioma by the AKT inhibitor, AZD5363","volume":"109","author":"Weller","year":"2017","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.canlet.2021.02.016_bib11","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1158\/1078-0432.CCR-12-1904","article-title":"mTORC1 inhibitors suppress meningioma growth in mouse models","volume":"19","author":"Pachow","year":"2013","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.canlet.2021.02.016_bib12","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008639","article-title":"Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship","volume":"6","author":"Shapiro","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2021.02.016_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11040545","article-title":"Identification of KIF11 as a novel target in meningioma","volume":"11","author":"Jungwirth","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2021.02.016_bib14","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/nrc3310","article-title":"Kinesins and cancer","volume":"12","author":"Rath","year":"2012","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.canlet.2021.02.016_bib15","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac6762","article-title":"The mitotic kinesin KIF11 is a driver of invasion, proliferation, and self-renewal in glioblastoma","volume":"7","author":"Venere","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2021.02.016_bib16","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s10637-007-9097-9","article-title":"A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial","volume":"26","author":"Lee","year":"2008","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.canlet.2021.02.016_bib17","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1038\/sj.bjc.6604264","article-title":"A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours","volume":"98","author":"Blagden","year":"2008","journal-title":"Br. J. Canc."},{"key":"10.1016\/j.canlet.2021.02.016_bib18","first-page":"21","article-title":"A University of Chicago consortium phase II trial of SB-715992 in advanced renal cell cancer","volume":"6","author":"Lee","year":"2008","journal-title":"Clin. Genitourin. Canc."},{"key":"10.1016\/j.canlet.2021.02.016_bib19","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/CAD.0b013e32834e74d6","article-title":"Phase I dose-escalation and pharmacokinetic study of ispinesib, a kinesin spindle protein inhibitor, administered on days 1 and 15 of a 28-day schedule in patients with no prior treatment for advanced breast cancer","volume":"23","author":"Gomez","year":"2012","journal-title":"Anti Canc. Drugs"},{"key":"10.1016\/j.canlet.2021.02.016_bib20","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1007\/s10637-015-0211-0","article-title":"First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumors","volume":"33","author":"LoRusso","year":"2015","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.canlet.2021.02.016_bib21","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00280-010-1346-5","article-title":"A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose","volume":"67","author":"Holen","year":"2011","journal-title":"Canc. Chemother. Pharmacol."},{"key":"10.1016\/j.canlet.2021.02.016_bib22","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41408-019-0240-6","article-title":"A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and\/or refractory multiple myeloma","volume":"9","author":"Lee","year":"2019","journal-title":"Blood Canc. J."},{"key":"10.1016\/j.canlet.2021.02.016_bib23","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1158\/1078-0432.CCR-09-1498","article-title":"Activity of the kinesin spindle protein inhibitor ispinesib (SB-715992) in models of breast cancer","volume":"16","author":"Purcell","year":"2010","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.canlet.2021.02.016_bib24","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1038\/leu.2009.101","article-title":"Inhibition of KSP by ARRY-520 induces cell cycle block and cell death via the mitochondrial pathway in AML cells","volume":"23","author":"Carter","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2021.02.016_bib25","doi-asserted-by":"crossref","first-page":"92106","DOI":"10.18632\/oncotarget.20785","article-title":"KIF11 is required for proliferation and self-renewal of docetaxel resistant triple negative breast cancer cells","volume":"8","author":"Jiang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2021.02.016_bib26","first-page":"155","article-title":"Characterization of KIF11 as a novel prognostic biomarker and therapeutic target for oral cancer","volume":"52","author":"Daigo","year":"2018","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.canlet.2021.02.016_bib27","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.4143\/crt.2018.460","article-title":"KIF11 functions as an oncogene and is associated with poor outcomes from breast cancer","volume":"51","author":"Zhou","year":"2019","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.canlet.2021.02.016_bib28","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3892\/ijo.2017.3834","article-title":"Five specific mitosis-associated genes correlate with poor prognosis for non-small cell lung cancer patients","volume":"50","author":"Schneider","year":"2017","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.canlet.2021.02.016_bib29","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000447303","article-title":"Overexpression of KIF11 in gastric cancer with intestinal mucin phenotype","volume":"84","author":"Imai","year":"2017","journal-title":"Pathobiology"},{"key":"10.1016\/j.canlet.2021.02.016_bib30","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1002\/cncr.30892","article-title":"A Phase 1 and 2 study of Filanesib alone and in combination with low-dose dexamethasone in relapsed\/refractory multiple myeloma","volume":"123","author":"Shah","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2021.02.016_bib31","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s10637-007-9098-8","article-title":"Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck","volume":"26","author":"Tang","year":"2008","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.canlet.2021.02.016_bib32","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.3324\/haematol.2017.168666","article-title":"The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma","volume":"102","author":"Hern\u00e1ndez-Garc\u00eda","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.canlet.2021.02.016_bib33","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.3109\/10428194.2015.1004167","volume":"56","author":"O'Connor","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.canlet.2021.02.016_bib34","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1002\/cncr.30174","article-title":"A phase 1 dose-escalation study of filanesib plus bortezomib and dexamethasone in patients with recurrent\/refractory multiple myeloma","volume":"122","author":"Chari","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2021.02.016_bib35","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s10637-009-9374-x","article-title":"A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors","volume":"29","author":"Burris","year":"2011","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.canlet.2021.02.016_bib36","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.3109\/10428194.2015.1020058","article-title":"The novel kinesin spindle protein (KSP) inhibitor SB-743921 exhibits marked activity in in vivo and in vitro models of aggressive large B-cell lymphoma","volume":"56","author":"Bongero","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.canlet.2021.02.016_bib37","first-page":"4373","article-title":"ARRY-520, a novel KSP inhibitor with potent activity in hematological and taxane-resistant tumor models","volume":"29","author":"Woessner","year":"2009","journal-title":"Anticancer Res."},{"key":"10.1016\/j.canlet.2021.02.016_bib38","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1471-2407-6-22","article-title":"Increased therapeutic potential of an experimental anti-mitotic inhibitor SB715992 by genistein in PC-3 human prostate cancer cell line","volume":"6","author":"Davis","year":"2006","journal-title":"BMC Canc."},{"key":"10.1016\/j.canlet.2021.02.016_bib39","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/0092-8674(95)90142-6","article-title":"Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo","volume":"83","author":"Blangy","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2021.02.016_bib40","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1126\/science.286.5441.971","article-title":"Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen","volume":"286","author":"Mayer","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.canlet.2021.02.016_bib41","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s10637-011-9660-2","article-title":"Phase I\/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia","volume":"30","author":"Kantarjian","year":"2012","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.canlet.2021.02.016_bib42","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00280-011-1667-z","article-title":"A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors","volume":"69","author":"Infante","year":"2012","journal-title":"Canc. Chemother. Pharmacol."},{"key":"10.1016\/j.canlet.2021.02.016_bib43","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/1479-5876-7-63","article-title":"KSP inhibitor ARRY-520 as a substitute for Paclitaxel in Type I ovarian cancer cells","volume":"7","author":"Kim","year":"2009","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.canlet.2021.02.016_bib44","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s10637-007-9103-2","article-title":"A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168)","volume":"26","author":"Knox","year":"2008","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.canlet.2021.02.016_bib45","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J. Basic Clin. Pharm."},{"key":"10.1016\/j.canlet.2021.02.016_bib46","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1002\/pbc.22056","article-title":"Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing Program","volume":"53","author":"Carol","year":"2009","journal-title":"Pediatr. Blood Canc."},{"key":"10.1016\/j.canlet.2021.02.016_bib47","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1158\/1535-7163.MCT-19-0154","article-title":"Is the fate of clinical candidate arry-520 already sealed? Predicting resistance in eg5-inhibitor complexes","volume":"18","author":"Indorato","year":"2019","journal-title":"Mol. Canc. Therapeut."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383521000896?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383521000896?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T15:54:33Z","timestamp":1759593273000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383521000896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":47,"alternative-id":["S0304383521000896"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2021.02.016","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"KIF11 inhibitors filanesib and ispinesib inhibit meningioma growth in vitro and in vivo","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2021.02.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}